Clinical outcomes of post-remission therapy using 90yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical outcomes of post-remission therapy using 90yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma

Published:2011-02-19 Issue:9 Volume:90 Page:1075-1082
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Han Eun Ji,Lee Sung-Eun,Kim Sung Hoon,Sohn Hyung Sun,Jung Seung Eun,Park Gyeongsin,Choi Byung-Ock,Lee Sang-Nam,Yang Suk-Woo,Han Kyungja,Cho Seok-Goo

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-011-1191-6.pdf

Reference20 articles.

1. Tilly H, Dreyling M (2009) Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(4):110–112

2. Murawski N, Zwick C, Pfreundschuh M (2010) Unresolved issues in diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 10:387–402

3. Brusamolino E (2009) First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions. Haematologica 94:1194–1198

4. Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

5. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329: 987–994

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials;Cancers;2021-11-07

2. Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma;Cancer Chemotherapy and Pharmacology;2016-08-30

3. The use of Yttrium-90 Ibritumomab Tiuxetan ( 90 Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation;Współczesna Onkologia;2015

4. Yttrium-90 Ibritumomab Tiuxetan (Zevalin®);Handbook of Therapeutic Antibodies;2014-08-12

5. Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma;Blood and Lymphatic Cancer: Targets and Therapy;2014-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3